title: [Adjuvants].
abstract: It is estimated that only 5% of all patients who can principally benefit from specific immunotherapy (SIT) undergo this treatment. SIT represents the only curative treatment for allergic disorders and efficacy has been demonstrated with various allergens. There is an urgent demand for the development of safe preparations with enhanced efficacy achievable by only a few administrations. Adjuvants are pharmacological or immunological acting molecules modifying the specific immunological response to allergens. In vaccine technology, adjuvants are broadly used to enhance immunogenicity of highly purified antigens with low immune stimulating activity. Adjuvants may target to a retarded allergen release, a modulation of the immune system, or can be used as vector systems to transport allergens and adjuvants effectively to target cells.
authors.affiliation: Klinik für Hautkrankheiten, Ambulanz für Allergologie, Berufsdermatologie und Umweltmedizin, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland. r.brehler@uni-muenster.de.
authors.forename: R
authors.initials: R
authors.lastname: Brehler
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000485:Allergens / Q000276:immunology* / Q000627:therapeutic use*; D000818:Animals; D003888:Desensitization, Immunologic / Q000379:methods*; D019317:Evidence-Based Medicine; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000485:Allergens
keywords: Allergen immunotherapy; Allergy; Antigens; Immunostimulation; Vector systems